BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodríguez Y, Gallo JE, Salazar-Uribe JC, Santander MJ, Cala MP, Zapata W, Zapata MI, Manrique R, Pardo-Oviedo JM, Camacho B, Ramírez-Santana C, Anaya JM; CP-COVID-19 group. COVID-19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun 2021;118:102598. [PMID: 33524876 DOI: 10.1016/j.jaut.2021.102598] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 30.0] [Reference Citation Analysis]
Number Citing Articles
1 Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, Carter RE, Paneth NS, Sullivan DJ, Morkeberg OH, Wright RS, Fairweather D, Bruno KA, Shoham S, Bloch EM, Focosi D, Henderson JP, Juskewitch JE, Pirofski L, Grossman BJ, Tobian AA, Franchini M, Ganesh R, Hurt RT, Kay NE, Parikh SA, Baker SE, Buchholtz ZA, Buras MR, Clayburn AJ, Dennis JJ, Diaz Soto JC, Herasevich V, Klompas AM, Kunze KL, Larson KF, Mills JR, Regimbal RJ, Ripoll JG, Sexton MA, Shepherd JR, Stubbs JR, Theel ES, van Buskirk CM, van Helmond N, Vogt MN, Whelan ER, Wiggins CC, Winters JL, Casadevall A, Joyner MJ. Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma A Systematic review and meta-analysis.. [DOI: 10.1101/2023.01.11.23284347] [Reference Citation Analysis]
2 Oscar E, Jhonathan R, Adriana R, Leonardo A, Nicolás A, Carolina S, Andrés H, Daniel W, David A. Advance Market Commitments (AMC) model application for Colombian purchase strategy of COVID-19 vaccines. Vaccine: X 2022;12:100197. [DOI: 10.1016/j.jvacx.2022.100197] [Reference Citation Analysis]
3 Passos Mansoldo FR, Garrett R, da Silva Cardoso V, Alves MA, Vermelho AB. Metabology: Analysis of metabolomics data using community ecology tools. Analytica Chimica Acta 2022;1232:340469. [DOI: 10.1016/j.aca.2022.340469] [Reference Citation Analysis]
4 Lundstrom K, Hromić-Jahjefendić A, Bilajac E, Aljabali AAA, Baralić K, Sabri NA, Shehata EM, Raslan M, Ferreira ACBH, Serrano-Aroca Á, Tambuwala MM, Uversky VN, Azevedo V, Alzahrani KJ, Alsharif KF, Halawani IF, Alzahrani FM, Barh D. COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity. Cell Signal 2022;:110495. [PMID: 36252792 DOI: 10.1016/j.cellsig.2022.110495] [Reference Citation Analysis]
5 Pius-sadowska E, Niedźwiedź A, Kulig P, Baumert B, Sobuś A, Rogińska D, Łuczkowska K, Ulańczyk Z, Wnęk S, Karolak I, Paczkowska E, Kotfis K, Kawa M, Stecewicz I, Zawodny P, Machaliński B. CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 Course. IJMS 2022;23:11338. [DOI: 10.3390/ijms231911338] [Reference Citation Analysis]
6 Zhang Q, Pizzorno A, Miorin L, Bastard P, Gervais A, Le Voyer T, Bizien L, Manry J, Rosain J, Philippot Q, Goavec K, Padey B, Cupic A, Laurent E, Saker K, Vanker M, Särekannu K, García-Salum T, Ferres M, Le Corre N, Sánchez-Céspedes J, Balsera-Manzanero M, Carratala J, Retamar-Gentil P, Abelenda-Alonso G, Valiente A, Tiberghien P, Zins M, Debette S, Meyts I, Haerynck F, Castagnoli R, Notarangelo LD, Gonzalez-Granado LI, Dominguez-Pinilla N, Andreakos E, Triantafyllia V, Rodríguez-Gallego C, Solé-Violán J, Ruiz-Hernandez JJ, Rodríguez de Castro F, Ferreres J, Briones M, Wauters J, Vanderbeke L, Feys S, Kuo CY, Lei WT, Ku CL, Tal G, Etzioni A, Hanna S, Fournet T, Casalegno JS, Queromes G, Argaud L, Javouhey E, Rosa-Calatrava M, Cordero E, Aydillo T, Medina RA, Kisand K, Puel A, Jouanguy E, Abel L, Cobat A, Trouillet-Assant S, García-Sastre A, Casanova JL; COVID Human Genetic Effort, Etablissement Français du Sang Study Group, Constances Cohort, 3C-Dijon Study, Cerba HealthCare Group, Lyon Antigrippe Working Group, REIPI INF Working Group. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J Exp Med 2022;219. [PMID: 36112363 DOI: 10.1084/jem.20220514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Casanova JL, Abel L. From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. Cell 2022;185:3086-103. [PMID: 35985287 DOI: 10.1016/j.cell.2022.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Mathian A, Breillat P, Dorgham K, Bastard P, Charre C, Lhote R, Quentric P, Moyon Q, Mariaggi AA, Mouries-Martin S, Mellot C, Anna F, Haroche J, Cohen-Aubart F, Sterlin D, Zahr N, Gervais A, Le Voyer T, Bizien L, Amiot Q, Pha M, Hié M, Chasset F, Yssel H, Miyara M, Charneau P, Ghillani-Dalbin P, Casanova JL, Rozenberg F, Amoura Z, Gorochov G. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α. Ann Rheum Dis 2022:annrheumdis-2022-222549. [PMID: 35973806 DOI: 10.1136/ard-2022-222549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Esteban I, Panighetti MT, Polack FP. Post-trial follow-up after a randomized clinical trial of COVID-19 convalescent plasma. Gates Open Res 2022;6:110. [DOI: 10.12688/gatesopenres.13725.1] [Reference Citation Analysis]
10 Laudanski K, Okeke T, Siddiq K, Hajj J, Restrepo M, Gullipalli D, Song WC. A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce. Sci Rep 2022;12:13658. [PMID: 35953544 DOI: 10.1038/s41598-022-17011-7] [Reference Citation Analysis]
11 Elizbeth Alvarez Sánchez M, Nolasco Ontiveros E, Arreola R, Montserrat Espinosa González A, María García Bores A, Eduardo López Urrutia R, Peñalosa Castro I, del Socorro Sánchez Correa M, Antonio Estrella Parra E. Lipidomics as a Tool in the Diagnosis and Clinical Therapy. Fatty Acids - Recent Advances [Working Title] 2022. [DOI: 10.5772/intechopen.105857] [Reference Citation Analysis]
12 Khorramdelazad H, Kazemi MH, Azimi M, Aghamajidi A, Mehrabadi AZ, Shahba F, Aghamohammadi N, Falak R, Faraji F, Jafari R. Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019. Eur J Pharmacol 2022;927:175051. [PMID: 35618037 DOI: 10.1016/j.ejphar.2022.175051] [Reference Citation Analysis]
13 Faist A, Janowski J, Kumar S, Hinse S, Çalışkan DM, Lange J, Ludwig S, Brunotte L. Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond. Cells 2022;11:2198. [DOI: 10.3390/cells11142198] [Reference Citation Analysis]
14 Karu N, Kindt A, Lamont L, van Gammeren AJ, Ermens AAM, Harms AC, Portengen L, Vermeulen RCH, Dik WA, Langerak AW, van der Velden VHJ, Hankemeier T. Plasma Oxylipins and Their Precursors Are Strongly Associated with COVID-19 Severity and with Immune Response Markers. Metabolites 2022;12:619. [DOI: 10.3390/metabo12070619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Chiale C, Greene TT, Zuniga EI. Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection. Immunol Rev 2022. [PMID: 35775361 DOI: 10.1111/imr.13113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
16 Rojas M, Rodríguez Y, Hernández JC, Díaz-coronado JC, Vergara JAD, Vélez VP, Mancilla JP, Araujo I, Yepes JT, Ricaurte OB, Pardo-oviedo JM, Monsalve DM, Acosta-ampudia Y, Ramírez-santana C, García PG, Landinez LA, Correales LD, Grass JS, Pérez CR, López GS, Mateus N, Mancera L, Devia RR, Orjuela JE, Parra-moreno CR, Buitrago AA, Ordoñez IE, Osorio CF, Ballesteros N, Patiño LH, Castañeda S, Muñoz M, Ramírez JD, Bastard P, Gervais A, Bizien L, Casanova J, Camacho B, Gallo JE, Gómez O, Rojas-villarraga A, Pérez CE, Manrique R, Mantilla RD, Anaya J. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07560-7] [Reference Citation Analysis]
17 Bastard P, Vazquez S, Liu J, Laurie MT, Wang CY, Gervais A, Le Voyer T, Bizien L, Zamecnik C, Philippot Q, Rosain J, Catherinot E, Willmore A, Mitchell AM, Bair R, Garçon P, Kenney H, Fekkar A, Salagianni M, Poulakou G, Siouti E, Sahanic S, Tancevski I, Weiss G, Nagl L, Manry J, Duvlis S, Arroyo-sánchez D, Paz Artal E, Rubio L, Perani C, Bezzi M, Sottini A, Quaresima V, Roussel L, Vinh DC, Reyes LF, Garzaro M, Hatipoglu N, Boutboul D, Tandjaoui-lambiotte Y, Borghesi A, Aliberti A, Cassaniti I, Venet F, Monneret G, Halwani R, Sharif-askari NS, Danielson J, Burrel S, Morbieu C, Stepanovskyy Y, Bondarenko A, Volokha A, Boyarchuk O, Gagro A, Neuville M, Neven B, Keles S, Hernu R, Bal A, Novelli A, Novelli G, Saker K, Ailioaie O, Antolí A, Jeziorski E, Rocamora-blanch G, Teixeira C, Delaunay C, Lhuillier M, Le Turnier P, Zhang Y, Mahevas M, Pan-hammarström Q, Abolhassani H, Bompoil T, Dorgham K, Gorochov G, Laouenan C, Rodríguez-gallego C, Ng LFP, Renia L, Pujol A, Belot A, Raffi F, Allende LM, Martinez-picado J, Ozcelik T, Keles S, Imberti L, Notarangelo LD, Troya J, Solanich X, Zhang S, Puel A, Wilson MR, Trouillet-assant S, Abel L, Jouanguy E, Ye CJ, Cobat A, Thompson LM, Andreakos E, Zhang Q, Anderson MS, Casanova J, Derisi JL, Abel L, Achille C, Aiuti A, Al-muhsen S, Al-mulla F, Anderson MS, Andreakos E, Angelini M, Arias AA, Aytekin G, Baldanti F, Feldman HB, Belot A, Bergami F, Biggs CM, Bogunovic D, Bolze A, Bondarenko A, Bousfiha AA, Brodin P, Bryceson Y, Bustamante CD, Butte MJ, Casari G, Christodoulou J, Condino-neto A, Constantinescu SN, Conti F, Cooper MA, Dalgard CL, Desai M, Drolet BA, El Baghdadi J, Ergun R, Ergun D, Espinosa-padilla S, Fellay J, Flores C, Franco JL, Froidure A, Ghirardello S, Gregersen PK, Grimbacher B, Haerynck F, Hagin D, Halwani R, Hammarström L, Heath JR, Henrickson SE, Hsieh EW, Husebye E, Imai K, Itan Y, Jarvis ED, Kanat F, Karamitros T, Kisand K, Kopcha V, Korda M, Ku C, Lau Y, Ling Y, Lucas CL, Maniatis T, Mansouri D, Maródi L, Meyts I, Milner JD, Mironska K, Mogensen TH, Mojoli F, Morandeira F, Morio T, Ng LF, Notarangelo LD, Novelli A, Novelli G, O'farrelly C, Okada S, Okamoto K, Ozcelik T, Pagani M, Pan-hammarström Q, Pape JW, de Diego RP, Perlin DS, Pesole G, Pession A, Piralla A, Planas AM, Prando C, Pujol A, Quintana-murci L, Ramaswamy S, Renia L, Resnick I, Rigo-bonnin R, Rodríguez-gallego C, Sancho-shimizu V, Sediva A, Seppänen MR, Shahrooei M, Shcherbina A, Slaby O, Snow AL, Soler-palacín P, Spaan AN, Tancevski I, Tangye SG, Abou Tayoun A, Tulek B, Turvey SE, Uddin KMF, Uddin M, Clément B, Abe-jones Y, Asthana S, Bhide S, Calfee CS, Carrillo SA, Chak S, Collins Z, Erle DJ, Fragiadakis GK, Ghale R, Hendrickson CM, Jauregui A, Kangelaris KN, Krummel MF, Langelier CR, Lea T, Lee D, Leligdowicz A, Leroux C, Lota R, Matthay M, Nguyen V, Patel R, Pierce L, Prasad P, Rao AA, Rashid A, Rodriguez N, Samad B, Shaw C, Sigman A, Tang K, Altamirano LT, Ward A, Willmore A, Wilson M, Woodruff PG, Abel L, Allavena C, Andrejak C, Angoulvant F, Azoulay C, Bachelet D, Bartoli M, Basmaci R, Behilill S, Beluze M, Benech N, Benkerrou D, Bhavsar K, Bitker L, Bouadma L, Bouscambert M, Paz PC, Cervantes-gonzalez M, Chair A, Chirouze C, Coelho A, Cordel H, Couffignal C, Couffin-cadiergues S, d’Ortenzio E, De Montmollin E, Debard A, Debray M, Deplanque D, Descamps D, Desvallée M, Diallo A, Diehl J, Diouf A, Dorival C, Dubos F, Duval X, Eloy P, Enouf V, Epaulard O, Esperou H, Esposito-farese M, Etienne M, Garot D, Gault N, Gaymard A, Ghosn J, Gigante T, Gilg M, Goehringer F, Guedj J, Hoctin A, Hoffmann I, Houas I, Hulot J, Jaafoura S, Kafif O, Kaguelidou F, Kali S, Kerroumi Y, Khalil A, Khan C, Kimmoun A, Laine F, Laouénan C, Laribi S, Le M, Le Bris C, Le Gac S, Le Hingrat Q, Le Mestre S, Le Nagard H, Lemaignen A, Lemee V, Lescure F, Letrou S, Levy Y, Lina B, Lingas G, Lucet JC, Machado M, Malvy D, Mambert M, Manuel A, Mentré F, Meziane A, Mouquet H, Mullaert J, Neant N, Nguyen D, Noret M, Papadopoulos A, Paul C, Peiffer-smadja N, Peigne V, Petrov-sanchez V, Peytavin G, Pham H, Picone O, Piquard V, Poissy J, Puéchal O, Rosa-calatrava M, Rossignol B, Rossignol P, Roy C, Schneider M, Su R, Tardivon C, Tellier M, Téoulé F, Terrier O, Timsit J, Tual C, Tubiana S, Van Der Werf S, Vanel N, Veislinger A, Visseaux B, Wiedemann A, Yazdanpanah Y; COVID HGE consortium, French COVID study group, COMET consortium. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci Immunol . [DOI: 10.1126/sciimmunol.abp8966] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
18 Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Mégarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs CM, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Ozcelik T, Keles S, Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY, Shcherbina A, Lau YL, Leung D, Coulongeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Venet F, Monneret G, Nussenzweig MC, Arrestier R, Boudhabhay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari FS, Dorgham K, Sallette J, Sedkaoui SM, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh DC, Erikstrup C, Condino-Neto A, Prando C, Bondarenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S, Anderson MS, Boisson B, Béziat V, Zhang SY, Andreakos E, Hermine O, Pujol A, Peterson P, Mogensen TH, Rowen L, Mond J, Debette S, de Lamballerie X, Burdet C, Bouadma L, Zins M, Soler-Palacin P, Colobran R, Gorochov G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen PK, Piemonti L, Rodríguez-Gallego C, Notarangelo LD, Su HC, Kisand K, Okada S, Puel A, Jouanguy E, Rice CM, Tiberghien P, Zhang Q, Casanova JL, Abel L, Cobat A; HGID Lab., COVID Clinicians., COVID-STORM Clinicians., NIAID Immune Response to COVID Group., NH-COVAIR Study Group., Danish CHGE., Danish Blood Donor Study., St. James's Hospital, SARS CoV2 Interest Group., French COVID Cohort Study Group., Imagine COVID-Group., Milieu Intérieur Consortium., CoV-Contact Cohort., Amsterdam UMC Covid-19 Biobank Investigators., COVID Human Genetic Effort., CP-COVID-19 Group., CONSTANCES cohort., 3C-Dijon Study., Cerba Health-Care., Etablissement Français du Sang Study group. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A 2022;119:e2200413119. [PMID: 35576468 DOI: 10.1073/pnas.2200413119] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
19 Puel A, Bastard P, Bustamante J, Casanova JL. Human autoantibodies underlying infectious diseases. J Exp Med 2022;219:e20211387. [PMID: 35319722 DOI: 10.1084/jem.20211387] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
20 Mortezaee K, Majidpoor J. CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives. Front Immunol 2022;13:864298. [DOI: 10.3389/fimmu.2022.864298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
21 Peng H, Chen F, Zuo Y, Huang B, Yang Y, Dang R. Mortality reduction in pediatric patients with severe fatal human adenoviral pneumonia treated with high titer neutralizing antibodies (NAbs) plasma: a retrospective cohort study. BMC Pediatr 2022;22:151. [PMID: 35317780 DOI: 10.1186/s12887-022-03225-1] [Reference Citation Analysis]
22 Kebria MM, Milan PB, Peyravian N, Kiani J, Khatibi S, Mozafari M. Stem cell therapy for COVID-19 pneumonia. Mol Biomed 2022;3:6. [PMID: 35174448 DOI: 10.1186/s43556-021-00067-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Al-Hajeri H, Baroun F, Abutiban F, Al-Mutairi M, Ali Y, Alawadhi A, Albasri A, Aldei A, AlEnizi A, Alhadhood N, Al-Herz A, Alkadi A, Alkanderi W, Almathkoori A, Almutairi N, Alsayegh S, Alturki A, Bahbahani H, Dehrab A, Ghanem A, Haji Hasan E, Hayat S, Saleh K, Tarakmeh H. Therapeutic role of immunomodulators during the COVID-19 pandemic - a narrative review. Postgrad Med 2022. [PMID: 35086413 DOI: 10.1080/00325481.2022.2033563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Chen LF, Yang CD, Cheng XB. Anti-Interferon Autoantibodies in Adult-Onset Immunodeficiency Syndrome and Severe COVID-19 Infection. Front Immunol 2021;12:788368. [PMID: 35003106 DOI: 10.3389/fimmu.2021.788368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Charvet B, Brunel J, Pierquin J, Iampietro M, Decimo D, Queruel N, Lucas A, del Mar Encabo-berzosa M, Arenaz I, Marmolejo TP, Morales FVB, Gonzalez AIG, Maldonado AC, Rivero CL, Mathieu C, Küry P, Flores-rivera J, Rios SA, de Oca GSM, Schoorlemmer J, Horvat B, Perron H. SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients.. [DOI: 10.1101/2022.01.18.21266111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen L, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Mégarbane B, Triantafyllia V, Fekkar A, Heath J, Franco J, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte O, Zhang Y, Snow A, Holland S, Biggs C, Moncada-Vélez M, Arias A, Lorenzo L, Boucherit S, Anglicheau D, Planas A, Haerynck F, Duvlis S, Nussbaum R, Ozcelik T, Keles S, Bousfiha A, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarstrom Q, Hammarstrom L, Dupont A, Kurolap A, Metz C, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros L, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye S, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann N, Shcherbina A, Lau YL, Leung D, Coulongeat M, Marlet J, Koning R, Reyes L, Chauvineau-Grenier A, Venet F, Monneret G, Nussenzweig M, Arrestier R, Boudhabhay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer A, Kennelly S, Bourke N, Halwani R, Sharif-Askari F, Dorgham K, Sallette J, Mehlal-Sedkaoui S, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh D, Erikstrup C, Condino-Neto A, Prando C, Bondarenko A, Spaan A, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton R, Mane S, Anderson M, Boisson B, Béziat V, Zhang SY, Andreakos E, Hermine O, Pujol A, Peterson P, Mogensen TH, Rowen L, Mond J, Debette S, deLamballerie X, Burdet C, Bouadma L, Zins M, Soler-Palacin P, Colobran R, Gorochov G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen P, Rodríguez-Gallego C, Piemonti L, Notarangelo L, Su H, Kisand K, Okada S, Puel A, Jouanguy E, Rice C, Tiberghien P, Zhang Q, Casanova JL, Abel L, Cobat A. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies. Res Sq 2022:rs. [PMID: 35043109 DOI: 10.21203/rs.3.rs-1225906/v1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Janssen LMF, Ghosh M, Lemaire F, Michael Pollard K, Hoet PHM. Exposure to silicates and systemic autoimmune-related outcomes in rodents: a systematic review. Part Fibre Toxicol 2022;19:4. [PMID: 34996462 DOI: 10.1186/s12989-021-00439-6] [Reference Citation Analysis]
28 Dhawan M, Priyanka, Parmar M, Angural S, Choudhary OP. Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks. Int J Surg 2022;97:106204. [PMID: 34974199 DOI: 10.1016/j.ijsu.2021.106204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
29 Beraud M, Goodhue Meyer E, Lozano M, Bah A, Vassallo R, Brown BL. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Bastard P, Zhang Q, Zhang S, Jouanguy E, Casanova J. Type I interferons and SARS-CoV-2: from cells to organisms. Current Opinion in Immunology 2022. [DOI: 10.1016/j.coi.2022.01.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
31 Esmaeili B, Esmaeili S, Pourpak Z. Immunological effects of convalescent plasma therapy for coronavirus: a scoping review. BMC Infect Dis 2021;21:1278. [PMID: 34952570 DOI: 10.1186/s12879-021-06981-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Danieli MG, Piga MA, Paladini A, Longhi E, Mezzanotte C, Moroncini G, Shoenfeld Y. Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease. Scand J Immunol 2021;94:e13101. [PMID: 34940980 DOI: 10.1111/sji.13101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
33 Rojas M, Ramírez-Santana C, Acosta-Ampudia Y, Monsalve DM, Rodriguez-Jimenez M, Zapata E, Naranjo-Pulido A, Suárez-Avellaneda A, Ríos-Serna LJ, Prieto C, Zambrano-Romero W, Valero MA, Rodríguez Y, Mantilla RD, Zhu C, Li QZ, Toro-Gutiérrez CE, Tobón GJ, Anaya JM. New insights into the taxonomy of autoimmune diseases based on polyautoimmunity. J Autoimmun 2022;126:102780. [PMID: 34923432 DOI: 10.1016/j.jaut.2021.102780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Liu Y, Zhou X, Liu X, Jiang X. The immunology and immunotherapy for COVID-19. Expert Rev Mol Med 2021;23:e24. [PMID: 34915958 DOI: 10.1017/erm.2021.30] [Reference Citation Analysis]
35 Paula HSC, Santiago SB, Araújo LA, Pedroso CF, Marinho TA, Gonçalves IAJ, Santos TAP, Pinheiro RS, Oliveira GA, Batista KA. An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic. Braz J Med Biol Res 2021;55:e11631. [PMID: 34909910 DOI: 10.1590/1414-431X2021e11631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Miller L, Berber E, Sumbria D, Rouse BT. Controlling the Burden of COVID-19 by Manipulating Host Metabolism. Viral Immunol 2021. [PMID: 34905407 DOI: 10.1089/vim.2021.0150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Laudanski K, Hajj J, Restrepo M, Siddiq K, Okeke T, Rader DJ. Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes. Biomedicines 2021;9:1791. [PMID: 34944606 DOI: 10.3390/biomedicines9121791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Acosta-ampudia Y, Monsalve DM, Rojas M, Rodríguez Y, Zapata E, Ramírez-santana C, Anaya J. Persistent Autoimmune Activation and Proinflammatory State in Post-COVID Syndrome.. [DOI: 10.1101/2021.11.17.21266457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Kageyama Y, Aida K, Kawauchi K, Morimoto M, Ebisui T, Akiyama T, Nakamura T. Jinhua Qinggan granule, a Chinese herbal medicine against COVID‑19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL‑6 and IFN‑γ: An open‑label, single‑arm pilot study. World Acad Sci J 2021;4. [DOI: 10.3892/wasj.2021.137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Lévy R, Zhang P, Bastard P, Dorgham K, Melki I, Hadchouel A, Hartoularos GC, Neven B, Castelle M, Roy C, Toin T, Berteloot L, Bizien L, Abid H, Burgard M, Houhou-Fidouh N, Rozenberg F, Jouanguy E, Ye CJ, Gorochov G, Zhang Q, Casanova JL. Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child. Proc Natl Acad Sci U S A 2021;118:e2114390118. [PMID: 34702736 DOI: 10.1073/pnas.2114390118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
41 Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, Grüner B, Ernst L, Spieth P, Lepper PM, Bentz M, Zinn S, Paul G, Kalbhenn J, Dollinger MM, Rosenberger P, Kirschning T, Thiele T, Appl T, Mayer B, Schmidt M, Drosten C, Wulf H, Kruse JM, Jungwirth B, Seifried E, Schrezenmeier H; CAPSID Clinical Trial Group. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest 2021;131:e152264. [PMID: 34464358 DOI: 10.1172/JCI152264] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 18.5] [Reference Citation Analysis]
42 Ligotti ME, Pojero F, Accardi G, Aiello A, Caruso C, Duro G, Candore G. Immunopathology and Immunosenescence, the Immunological Key Words of Severe COVID-19. Is There a Role for Stem Cell Transplantation? Front Cell Dev Biol 2021;9:725606. [PMID: 34595175 DOI: 10.3389/fcell.2021.725606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 Theken KN, Tang SY, Sengupta S, FitzGerald GA. The roles of lipids in SARS-CoV-2 viral replication and the host immune response. J Lipid Res 2021;:100129. [PMID: 34599996 DOI: 10.1016/j.jlr.2021.100129] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
44 Brox R, Achenbach S, Hackstein H. Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma. Transfusion 2021;61:3087-93. [PMID: 34546583 DOI: 10.1111/trf.16685] [Reference Citation Analysis]
45 Zhang S, Luo P, Xu J, Yang L, Ma P, Tan X, Chen Q, Zhou M, Song S, Xia H, Wang S, Ma Y, Yang F, Liu Y, Li Y, Ma G, Wang Z, Duan Y, Jin Y. Plasma Metabolomic Profiles in Recovered COVID-19 Patients without Previous Underlying Diseases 3 Months After Discharge. J Inflamm Res 2021;14:4485-501. [PMID: 34522117 DOI: 10.2147/JIR.S325853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
46 Anaya JM, Rojas M, Salinas ML, Rodríguez Y, Roa G, Lozano M, Rodríguez-Jiménez M, Montoya N, Zapata E, Monsalve DM, Acosta-Ampudia Y, Ramírez-Santana C; Post-COVID study group. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev 2021;20:102947. [PMID: 34509649 DOI: 10.1016/j.autrev.2021.102947] [Cited by in Crossref: 48] [Cited by in F6Publishing: 57] [Article Influence: 24.0] [Reference Citation Analysis]
47 Rojas M, Ramírez-santana C, Acosta-ampudia Y, Monsalve DM, Rodriguez-jimenez M, Zapata E, Naranjo-pulido A, Suárez-avellaneda A, Ríos-serna LJ, Prieto C, Zambrano-romero W, Valero MA, Mantilla RD, Zhu C, Li Q, Toro-gutiérrez CE, Tobón GJ, Anaya J. Polyautoimmunity Clusters as a New Taxonomy of Autoimmune Diseases.. [DOI: 10.1101/2021.08.15.21262029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Zaher K, Masango NE, Sobhi W, Kanouni KE, Semmeq A, Benguerba Y. In-silico Study of the Developed Hydroxychloroquine-based ACE2 Inhibitor Molecules Against COVID-19: Molecular Modeling and Docking. Eng Technol Appl Sci Res 2021;11:7336-7342. [DOI: 10.48084/etasr.4244] [Reference Citation Analysis]
49 Focosi D, Franchini M, Pirofski LA, Burnouf T, Fairweather D, Joyner MJ, Casadevall A. COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses 2021;13:1594. [PMID: 34452459 DOI: 10.3390/v13081594] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
50 Tabll AA, Shahein YE, Omran MM, Elnakib MM, Ragheb AA, Amer KE. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection. Hum Antibodies 2021;29:179-91. [PMID: 33998533 DOI: 10.3233/HAB-200441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
51 Anaya J, Rojas M, Salinas ML, Rodríguez Y, Roa G, Lozano M, Rodríguez-jiménez M, Montoya N, Zapata E, Monsalve DM, Acosta-ampudia Y, Ramírez-santana C, Post-COVID study group. Post-COVID Syndrome. A Case Series and Comprehensive Review.. [DOI: 10.1101/2021.07.17.21260655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Lingel H, Meltendorf S, Billing U, Thurm C, Vogel K, Majer C, Prätsch F, Roggenbuck D, Heuft HG, Hachenberg T, Feist E, Reinhold D, Brunner-Weinzierl MC. Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. J Autoimmun 2021;122:102682. [PMID: 34214763 DOI: 10.1016/j.jaut.2021.102682] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
53 Casadevall A, Dragotakes Q, Johnson PW, Senefeld JW, Klassen SA, Wright RS, Joyner MJ, Paneth N, Carter RE. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife 2021;10:e69866. [PMID: 34085928 DOI: 10.7554/eLife.69866] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
54 Acosta-Ampudia Y, Rojas M, Monsalve DM, Rodríguez Y, Ramírez-Santana C, Anaya JM. Comment on: Nature and Dimensions of the Systemic Hyper-inflammation and Its Attenuation by Convalescent Plasma in Severe COVID-19. J Infect Dis 2021;223:1833-4. [PMID: 33715012 DOI: 10.1093/infdis/jiab137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Kumar D, Gauthami S, Bayry J, Kaveri SV, Hegde NR. Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. Monoclon Antib Immunodiagn Immunother 2021;40:36-49. [PMID: 33900819 DOI: 10.1089/mab.2021.0004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
56 Casadevall A, Dragotakes Q, Johnson PW, Senefeld JW, Klassen SA, Wright RS, Joyner MJ, Paneth N, Carter RE. Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives? medRxiv 2021:2021. [PMID: 33851186 DOI: 10.1101/2021.04.07.21255089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]